Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Williams

Showing results (241-250 of 262) with videos related to

Pageof 27
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.
Communications Biology|July 9, 2025
Triggering AHR resolves TGF-β1 induced fibroblast activation and promotes AT1 cell regeneration in alveolar organoidsAndrew S Hagan, Scott Williams, Casey J N Mathison, et al.
Journal of Vascular Surgery|May 23, 2020
The Vascular Implant Surveillance and Interventional Outcomes (VISION) Coordinated Registry Network: An effort to advance evidence evaluation for vascular devicesGreg Tsougranis, Jens Eldrup-Jorgensen, Daniel Bertges, et al.
Nature Communications|August 10, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesA M Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
Molecular Cell|June 10, 2020
Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 NucleaseAlejandro Álvarez-Quilón, Jessica L Wojtaszek, Marie-Claude Mathieu, et al.
Transfusion|May 18, 2016
A targeted immunomic approach identifies diagnostic antigens in the human pathogen Babesia microtiEmmanuel Cornillot, Amina Dassouli, Niseema Pachikara, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
Pageof 27

Showing results (241-250 of 262) with videos related to

Sort By:
Pageof 27
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.
Communications Biology|July 9, 2025
Triggering AHR resolves TGF-β1 induced fibroblast activation and promotes AT1 cell regeneration in alveolar organoidsAndrew S Hagan, Scott Williams, Casey J N Mathison, et al.
Journal of Vascular Surgery|May 23, 2020
The Vascular Implant Surveillance and Interventional Outcomes (VISION) Coordinated Registry Network: An effort to advance evidence evaluation for vascular devicesGreg Tsougranis, Jens Eldrup-Jorgensen, Daniel Bertges, et al.
Nature Communications|August 10, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesA M Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
Molecular Cell|June 10, 2020
Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 NucleaseAlejandro Álvarez-Quilón, Jessica L Wojtaszek, Marie-Claude Mathieu, et al.
Transfusion|May 18, 2016
A targeted immunomic approach identifies diagnostic antigens in the human pathogen Babesia microtiEmmanuel Cornillot, Amina Dassouli, Niseema Pachikara, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With RadiationWanling Xie, Meredith M Regan, Marc Buyse, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
Pageof 27